Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Johnson and Johnson
Moodys
AstraZeneca
Dow

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,168,637

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,168,637 protect, and when does it expire?

Patent 8,168,637 protects JUVISYNC and is included in one NDA.

This patent has seventy patent family members in forty-three countries.

Summary for Patent: 8,168,637
Title:Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment of diabetes
Abstract: The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme ("DP-IV inhibitors") and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
Inventor(s): Edmondson; Scott D. (New York, NJ), Kim; Dooseop (Westfield, NJ), Maccoss; Malcolm (Freehold, NJ), Parmee; Emma R. (Scotch Plains, NJ), Weber; Ann E. (Scotch Plains, NJ), Xu; Jinyou (Scotch Plains, NJ)
Assignee: Merck Sharp & Dohme Corp. (Rahway, NJ)
Application Number:12/694,758
Patent Claim Types:
see list of patent claims
Composition; Compound; Use;

Drugs Protected by US Patent 8,168,637

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Merck Sharp Dohme JUVISYNC simvastatin; sitagliptin phosphate TABLET;ORAL 202343-004 Sep 18, 2012 DISCN Yes No   Start Trial   Start Trial Y METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE   Start Trial
Merck Sharp Dohme JUVISYNC simvastatin; sitagliptin phosphate TABLET;ORAL 202343-001 Oct 7, 2011 DISCN Yes No   Start Trial   Start Trial Y METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE   Start Trial
Merck Sharp Dohme JUVISYNC simvastatin; sitagliptin phosphate TABLET;ORAL 202343-005 Sep 18, 2012 DISCN Yes No   Start Trial   Start Trial Y METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
AstraZeneca
Merck
Colorcon
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.